News
-
Many of the winners at this year’s CPhI Pharma Awards, held on November 5 at the 2019 CPhI Worldwide meeting in Frankfurt, Germany, offer significant expertise in inhaled and nasal drug delivery, including Lonza, which… Read more . . .
-
Kind Consumer has announced the UK launch of its breath activated Voke 0.45mg nicotine inhaler, which will be available to consumers by direct online purchase at a price of £11.99. The Voke inhaler was approved by… Read more . . .
-
Inhaled drug developer Pulmatrix has announced the appointment of Nocion Therapeutics CEO Rick Batycky to its board of directors. Batycky was a founder of Civitas Therapeutics, which developed Inbrija inhaled levodopa and which was acquired by Acorda… Read more . . .
-
MannKind Corporation said that it has reached the second milestone in its development of Treprostinil Technosphere (“TreT”), a dry powder formulation of treprostinil for inhalation that the company is developing for the treatment of pulmonary arterial… Read more . . .
-
Insmed has announced the appointment of Martina Flammer as Chief Medical Officer, effective mid-December 2019. Flammer was most recently Senior VP Customer Value at Boehringer Ingelheim and her previous positions include VP Medicine, Regulatory Affairs… Read more . . .
-
Aptar has announced its acquisition of Noble International, which specializes in training devices and patient onboarding for drug delivery devices, including inhalers. Noble makes respiratory trainers for both MDIs and DPIs with a variety of… Read more . . .
-
Liquidia Technologies has announced the appointment of AbbVie VP of Global Commercial Development Katie Rielly-Gauvin to its board of directors for a term that will extend until company’s 2020 annual meeting. Prior to her position at… Read more . . .
-
After having been notified that CHMP was likely to issue a negative opinion regarding its MAA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis… Read more . . .
-
Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners;… Read more . . .
-
Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.